Showing results (91-100 of 151) with videos related to

Sort By:
Pageof 16
Diabetes, Obesity & Metabolism|January 9, 2025
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trialAmanda Siriwardana, Luke Buizen, Min Jun, et al.
BMJ Open|March 7, 2024
Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complicationsMustafa Arici, Samir Helmy Assaad-Khalil, Marcello Casaccia Bertoluci, et al.
Kidney International Reports|February 22, 2021
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin ReceptorMegumi Oshima, Akinori Hara, Tadashi Toyama, et al.
Contributions to Nephrology|June 1, 2011
Outcomes of patients with planned initiation of hemodialysis in the IDEAL trialJohn Collins, Bruce Cooper, Pauline Branley, et al.
Kidney International|February 17, 2012
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insightsIain C Macdougall, Simon D Roger, Angel de Francisco, et al.
Diabetes, Obesity & Metabolism|October 12, 2020
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomesBrendon L Neuen, Clare Arnott, Vlado Perkovic, et al.
Advances in Therapy|November 29, 2024
Baseline Characteristics of the DISCOVER CKD Prospective CohortCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Diabetes, Obesity & Metabolism|November 6, 2020
Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendationsChin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 4, 2025
Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trialBryony Beal, Luke Buizen, Emily K Yeung, et al.
Pageof 16